MicroPort NeuroTech (2172) Stock Overview

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial stent a balloon-expandable stent to treat intracranial atherosclerotic disease; Bridge, a rapamycin target eluting vertebral artery stent system; and Diveer, an intracranial balloon catheter to treat cerebral atherosclerosis stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; X-Track, and distal access catheter product; W-track, an intracranial aspiration catheter; and balloon protection guide catheter; and Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. Further, it provides Asahi Neurovascular Guidewires and U-track support catheter. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.